K-INBRE is the Kansas IDeA Network of Biomedical Research Excellence. In Kansas, the INBRE grant supports research strengths in cell and developmental biology. COBRE grants fund Centers of Biomedical Research Excellence. The COBRE grants support research in protein structure and function, epithelial cell physiology, drug development, infectious disease, and liver health and disease.
The INBRE grant for the state of Kansas is located at the University of Kansas Medical Center. The seven funded COBRE grants are located in the state of Kansas at Kansas State University, the University of Kansas-Lawrence, and the University of Kansas Medical Center.
The K-INBRE fosters inter-campus biomedical research among 10 campuses: the University of Kansas Medical Center, the University of Kansas in Lawrence, Kansas State University, Wichita State University, Emporia State University, Fort Hays State University, Haskell Indian Nations University, Pittsburg State University and Washburn University in Kansas, along with Langston University in Oklahoma. Its goals are to inspire outstanding undergraduates to pursue careers in biomedical research in Kansas, enhance research capacity through faculty development and retention, and expand the biomedical research infrastructure among participating universities. The principal investigator is Douglas E. Wright, PhD (firstname.lastname@example.org). Visit http://www.k-inbre.org/ to learn more.
Epithelial cell physiology represents a broad area of knowledge, including the study of the kidney, respiratory tract, gastrointestinal tract, pancreatic cells, reproductive organs, sensory organs and insect transmission of disease. A major goal of this COBRE grant is to advance the understanding of epithelial function in health and disease to create a strong foundation for translational research. The principal investigator is Daniel C. Marcus, DSc (email@example.com). To learn more, visit http://www.vet.k-state.edu/depts/ap/COBRE.
Examining protein structure-function relationships at the atomic and molecular level, junior and senior investigators throughout Kansas and the Midwest collaborate using state-of-the-art Core Lab facilities to explore how proteins function in health and disease. The principal investigator is Robert Hanzlik, PhD (firstname.lastname@example.org). Visit http://psf.cobre.ku.edu to learn more.
The Center for Cancer Experimental Therapeutics at the University of Kansas brings together researchers from the University of Kansas, both in Lawrence and at the Medical Center, Kansas State University and Emporia State University with an emphasis on fighting cancer through the discovery of potential drug therapies. Scientific projects at the leading edge of cancer research, interactions among researchers at the interface of chemistry and biology, and the strong mentoring ethic practiced by the center’s senior researchers will contribute to KU’s efforts toward achieving designation from the National Cancer Institute as a Comprehensive Cancer Center. The principal investigator is Barbara Timmermann, PhD (email@example.com). To learn more, visit http://ccet.cobre.ku.edu.
Building on success in preventing AIDS in animal trials using a DNA vaccine, junior and senior investigators examine novel molecular mechanisms for inhibiting replication of pathogenic microbes, emphasizing immunopathological responses to infectious agents and host antigens. The principal investigator is Joe Lutkenhaus, PhD (firstname.lastname@example.org). Visit http://www.kumc.edu/school-of-medicine/microbiology-molecular-genetics-and-immunology/cobre.html to learn more.
The Department of Pharmacology, Toxicology and Therapeutics at the University of Kansas School of Medicine studies the role of nuclear receptors in liver health and disease. Examining these receptors and exploring how they might respond to drugs may lead to new treatments for a variety of disorders, such as diabetes and atherosclerosis. The principal investigator is Hartmut W. Jaeschke, PhD (email@example.com). To learn more, visit http://www.kumc.edu/school-of-medicine/pharmacology-toxicology-and-therapeutics/faculty/hartmut-jaeschke-phd.html.
The Center for Molecular Analysis of Disease Pathways (CMADP), an NIH Center for Biomedical Research Excellence (COBRE), conducts multidisciplinary research to develop and implement cutting-edge technologies for elucidating the genetic, chemical, and physical mechanisms of biological processes involved in disease. The scientific emphasis of the Center is on the creation and implementation of enabling technologies that can be employed to identifying new therapeutic targets. This includes state of the art methods for gene sequencing, the genetic manipulation of model organisms, custom fluorescent molecular probes for monitoring physiological processes in model organisms, and microfluidic systems for manipulation and monitoring of biochemical pathways.The principal investigator is Susan Lunte (firstname.lastname@example.org). To learn more, visit http://cmadp.cobre.ku.edu/.
In an effort to regenerate diseased tissues caused by such maladies as spinal cord injuries, heart attacks and kidney failure, a multidisciplinary research team at the University of Kansas Medical Center examines cell development and differentiation in embryonic life. The principal investigator is Dale Abrahamson, PhD. (email@example.com). To learn more, visit http://www.kumc.edu/school-of-medicine/anatomy-and-cell-biology/nih-center-of-biomedical-research-excellence-(cobre).html.